Burden among participants with central disorders of hypersomnolence in six European countries.
Narcolepsy types 1 and 2 (NT1/NT2) and idiopathic hypersomnia (IH) are central disorders of hypersomnolence (CDHs) that significantly impact patients' quality of life (QoL). We investigated the recent medication use, comorbidities, and clinical burden among participants with CDHs from six European c…
Comparison of heart rate responses at respiratory event termination in children referred for assessment of hypersomnolence.
Adult studies have linked disorders of hypersomnolence to impaired heart rate (HR) control. We examined HR changes during obstructive and central respiratory events in children referred for assessment of hypersomnolence compared to controls. 20 children diagnosed with narcolepsy, 7 with idiopathic h…
Clinical correlates of sleep profiles in dementia with Lewy bodies: a latent class approach.
Rapid eye movement behavioral disorder (RBD) is a well-studied feature of dementia with Lewy bodies (DLB). However, patients with DLB report a significantly wider range of sleep symptoms than those of RBD. Our objective was to characterize profiles of sleep disturbances in DLB. Retrospective cross-s…
Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates: a plain language summary of publication.
What is this summary about?This plain language summary describes an article about the RESTORE clinical study. RESTORE looked at how people with narcolepsy (PWN) felt after switching from taking immediate-release oxybate twice each night (TN-OXB) to taking extended-release sodium oxybate once at nigh…
Novel 3‑Heteroaryl Pyrrolidine and Piperidine Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, namely, Narcolepsy and Hypersomnia.
Provided herein are novel 3-heteroaryl pyrrolidine and piperidine compounds as orexin receptor agonists, pharmaceutical compositions, use of such compounds in treating sleep disorders, namely, narcolepsy and hypersomnia, and processes for preparing such compounds.
Hypocretin-1/ Orexin-A fragment1-16 as a potential surrogate marker for diagnosing narcolepsy type 1.
Loss of cerebrospinal fluid hypocretin-1/orexin-A (Hcrt-1) immunoreactivity is a biomarker for narcolepsy type 1 (NT1). The current radioimmunoassay (RIA) does not allow precise quantification, limiting the assessment of disease severity and evolution. This study aimed to reproduce previously propos…
Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.
Hypocretin-1/Orexin-A is associated with stabilization of the sleep/wake cycle. Reductions of cerebrospinal fluid (CSF) concentrations of orexin-A, as determined by radioimmunoassay (RIA), are considered consistent with the diagnosis of narcolepsy type 1 (NT1). However, measuring full-length orexin-…
Assessment of readiness in the diagnosis and management of central disorders of hypersomnolence: A survey of sleep medicine program directors and fellowship graduates.
Central disorders of hypersomnolence (CDH), including narcolepsy, idiopathic hypersomnia, and recurrent hypersomnia, are rare conditions that pose challenges in sleep medicine fellowship training. Limited exposure to these disorders, variability in training experiences, and growing complexity of dia…